1. Home
  2. VBF vs BWAY Comparison

VBF vs BWAY Comparison

Compare VBF & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VBF
  • BWAY
  • Stock Information
  • Founded
  • VBF 1970
  • BWAY 2003
  • Country
  • VBF United States
  • BWAY Israel
  • Employees
  • VBF N/A
  • BWAY N/A
  • Industry
  • VBF Trusts Except Educational Religious and Charitable
  • BWAY Medical/Dental Instruments
  • Sector
  • VBF Finance
  • BWAY Health Care
  • Exchange
  • VBF Nasdaq
  • BWAY Nasdaq
  • Market Cap
  • VBF 177.3M
  • BWAY 177.4M
  • IPO Year
  • VBF N/A
  • BWAY 2019
  • Fundamental
  • Price
  • VBF $15.60
  • BWAY $10.93
  • Analyst Decision
  • VBF
  • BWAY Strong Buy
  • Analyst Count
  • VBF 0
  • BWAY 3
  • Target Price
  • VBF N/A
  • BWAY $13.17
  • AVG Volume (30 Days)
  • VBF 45.5K
  • BWAY 52.9K
  • Earning Date
  • VBF 01-01-0001
  • BWAY 03-05-2025
  • Dividend Yield
  • VBF 5.18%
  • BWAY N/A
  • EPS Growth
  • VBF N/A
  • BWAY N/A
  • EPS
  • VBF N/A
  • BWAY 0.04
  • Revenue
  • VBF N/A
  • BWAY $38,631,000.00
  • Revenue This Year
  • VBF N/A
  • BWAY $388.82
  • Revenue Next Year
  • VBF N/A
  • BWAY $18.70
  • P/E Ratio
  • VBF N/A
  • BWAY $138.73
  • Revenue Growth
  • VBF N/A
  • BWAY 34.19
  • 52 Week Low
  • VBF $13.68
  • BWAY $4.61
  • 52 Week High
  • VBF $16.27
  • BWAY $11.25
  • Technical
  • Relative Strength Index (RSI)
  • VBF 51.01
  • BWAY 68.25
  • Support Level
  • VBF $15.44
  • BWAY $10.08
  • Resistance Level
  • VBF $15.64
  • BWAY $11.25
  • Average True Range (ATR)
  • VBF 0.19
  • BWAY 0.35
  • MACD
  • VBF 0.04
  • BWAY 0.18
  • Stochastic Oscillator
  • VBF 43.59
  • BWAY 84.55

About VBF Invesco Bond Fund

Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: